Abnormal AKR1C1 expression induces the development of drug resistance in chemotherapy of cancers including NSCLC, breast cancer, and ovarian cancer (Chen et al., 2017a). This evidence concerns the gene AKR1C1 and non-small cell lung carcinoma.